Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis†
Inflammatory Bowel Diseases2009Vol. 16(4), pp. 620–629
Citations Over TimeTop 10% of 2009 papers
Daniel C. Baumgart, Stephan R. Targan, Axel Dignaß, Lloyd Mayer, Gert Van Assche, Daan W. Hommes, Stephen B. Hanauer, Uma Mahadevan, Walter Reinisch, Scott E. Plevy, Bruce Salzberg, Alan L. Buchman, G Mechkov, Zahariy Krastev, James N. Lowder, Matthew Frankel, William J. Sandborn
Abstract
Treatment with visilizumab induced symptomatic response and clinical response. Results with 5 microg/kg/day were similar to those observed with higher doses.
Related Papers
- THE EXPERIMENTAL STUDY OF THE RELATED CYTOKINES FOR IN PATIENTS WITH ULCERATIVE COLITIS.(2005)
- Investigation of Serum NO Levels in Patients With Ulcerative Colitis(2002)
- Determination of plasma P-selection in patients with ulcerative colitis and their clinical significance(2004)
- The severity correlation of TNF-α,IL-6 and IL-8 levels in plasma in patients with ulcerative colitis and their clinical significances(2008)
- → To study on nutritional status in patients with ulcerative colitis(2023)